AstraZeneca PLC - American Depositary Shares (AZN)

Amgen launches AmgenNow, offering Repatha at $239 per month, expanding direct access for U.S. patients with no insurer restrictions.

Algen Biotechnologies partners with AstraZeneca in a $555 million deal to advance AI-driven CRISPR drug discovery and novel immunology therapies.

AstraZeneca and Daiichi Sankyo's Datroway improved survival outcomes over chemotherapy in advanced triple-negative breast cancer patients.

Quantum stocks have mooned in 2025, raising questions about whether their sky-high valuations reflect real breakthroughs or just speculation.

As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for sustainability. This dynamic landscape is giving rise to several high-growth sectors that are not only reshaping industries but also presenting unprecedented investment opportunities.

In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca (lurbinectedin) and Roche's (SIX: ROG, OTCQX: RHHBY) Tecentriq (atezolizumab), along with its subcutaneous formulation Tecentriq Hybreza. This landmark decision sanctions

All of these rising quantum computing stars could be massive winners over the long run.

Two under-the-radar health-tech stocks are seeing their Momentum scores surge in Benzinga's Edge Stock Rankings.

Thousand Oaks, CA – October 2, 2025 – Amgen (NASDAQ: AMGN) has witnessed a robust surge in its share price, climbing approximately 6% in recent trading sessions, culminating on October 2, 2025, to reach $296.93 USD. This significant uptick is attributed to a powerful combination of strategic manufacturing investments, a pivotal

The uncertainty about U.S. pharmaceutical tariffs shouldn't be as worrisome for AstraZeneca now.

September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

AstraZeneca (LSE: AZN, NASDAQ: AZN) has announced a significant strategic move to harmonize its stock market listings across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE). This ambitious plan aims to create a unified global platform for investors, replacing its current American Depositary

Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern.

The Board of AstraZeneca plc (NASDAQ: AZN) is recommending to shareholders a Harmonized Listing Structure for the company's ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE).

You won't need a huge amount of cash to invest in these great pharma stocks.

AstraZeneca Plc (NASDAQ: AZN) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent cash price w

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe."

Eli Lilly CEO Dave Ricks criticizes UK drug pricing and rebate rules as pharma giants scale back investments, warning of fewer new medicines.

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a niche segment has exploded into a multi-billion-dollar arena, driven by highly effective new medications, primarily GLP-1 receptor agonists, that are

AstraZeneca and Amgen secure CHMP support for Tezspire in nasal polyps and Koselugo in neurofibromatosis after strong Phase 3 trial results.